17. New Zealand Ministry of Health. Influenza Weekly Update 2010/39. Sep27 – 3 Oct, 2010. Disponible au : http://www.surv.esr.cri.nz/PDF_surveillance/Virology/FluWeekRpt/2010/FluWeekRpt201039.pdf

18. World Health Organization. Global Alert and Response (GAR). Influenza update. 8 Apr 2011. Disponible au : http://www.who.int/csr/disease/influenza/2011_04_08_GIP_surveillance/en/index.html

19. Australia Department of Health and Ageing. Influenza Surveillance Report No. 1, 2011, Reporting period Mar 19 – Apr 1, 2011. Disponible au : http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-ozflu-no1-11.htm

20. World Health Organization. Global Alert and Response (GAR). Avian Influenza Situation Updates. Disponible au : http://www.who.int/csr/disease/avian_influenza/updates/en/index.html

21. World Health Organization. Global Alert and Response (GAR). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. 11 Apr 2011. Disponible au : http://www.who.int/entity/csr/disease/avian_influenza/country/cases_table_2011_04_11/en/index.html

22. World Health Organization. Global Alert and Response (GAR). Current WHO phase of pandemic alert for avian influenza H5N1. Disponible au : http://www.who.int/csr/disease/avian_influenza/phase/en/index.html

23. World Health Organization. Update on human cases of highly pathogenic avian influenza A(H5N1) virus infection, 2010. Wkly Epidemiol Rec. 2011;86(10):161-6. Disponible au : http://www.who.int/wer/2011/wer8617.pdf

24. World Health Organization. Update on oseltamivir resistance in influenza A(H1N1)2009 viruses. Apr 6 2011. Disponible au : http://www.who.int/csr/disease/influenza/2011_04_08_weekly_web_update_oseltamivir_resistance.pdf

25. Lackenby A, Gilad JM, Pebody R, et coll. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill. 2011;16(5):pii=19784. Disponible au : http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19784

26. Comité consultatif national de l'immunisation (CCNI). Une déclaration d'un comité consultatif (DCC). Addendum à la déclaration sur le vaccin inactivé trivalent contre l'influenza saisonnière. Recommandations concernant l'utilisation du vaccin antigrippal trivalent inactivé intradermique (VTI-ID) pour 2010-2011. Disponible au : http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/11vol37/acs-dcc-4/index-fra.php

27. Comité consultatif national de l'immunisation (CCNI). Une déclaration d'un comité consultatif (DCC). Recommendations on the use of live, attenuated influenza vaccine (FluMist®): Supplemental Statement of Seasonal Influenza Vaccine for 2011-2012. Available from: http://www.phac-aspc.gc.ca/naci-ccni/index-eng.php#rec.

28. Comité consultatif national de l'immunisation (CCNI). Une déclaration d'un comité consultatif (DCC). MF59-adjuvanted trivalent influenza vaccine (Fluad®): Supplemental Statement of Seasonal Influenza Vaccine for 2011-2012. Available from: http://www.phac-aspc.gc.ca/naci-ccni/index-eng.php#rec.

29. Langley JM, Faughnan ME. Prevention of influenza in the general population. CMAJ. 2004;171(10):1213-22.

30. Smith S, Demicheli V, Di Pietrantonj C et col. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2006;2006(1):CD004879.

31. Negri E, Colombo C, Giordano L et coll. Influenza vaccine in healthy children: a meta-analysis. Vaccine. 2005;23(22):2851-61.

32. Manzoli L, Schioppa F, Boccia A et coll. The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr Infect Dis J. 2007;26(2):97-106.

33. Demicheli V, Rivelli D, Deeks JJ et coll. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2004;2004(3):CD001269.

34. Jefferson TO, Rivetti D, Di Pietrantonj C et coll. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007;2007(2):CD001269.
35. Govaert TM, Thijs CT, Masurel N et coll. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272(21):1661-5.

36. Praditsuwan R, Assantachai P, Wasi C et coll. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. J Med Assoc Thai. 2005;88(2):256-64.

37. Ohmit SE, Victor JC, Rotthoff JR et coll. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006;355(24):2513-22.

38. Herrera GA, Iwane MK, Cortese M et coll. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004. Vaccine. 2007;25(1):154-60.

39. Rivetti D, Jefferson T, Thomas R et coll. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2006;2006(3):CD004876.

40. Nichol KL, Nordin JD, Nelson DB et coll. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357:1373-81.

41. Poole PJ, Chacko E, Wood-Baker RW et coll. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;2006(1):CD002733.

42. Hak E, Buskens E, van Essen GA et coll. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med. 2005;165(3):274-80.

43. Nichol KL, Nordin J, Mullooly J et coll. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348(14):1322-32.

44. Looijmans-Van den Akker I, Verheij TS, Buskens E et coll. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care. 2006;29(8):1771-6.

45. Orenstein EW, De Serres G, Haber MJ et coll. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol. 2007;36:623-31.

46. Simonsen L. Commentary: observational studies and the art of accurately measuring influenza vaccine benefits. Int J Epidemiol. 2007;36:631-2.

47. Jackson LA, Jackson ML, Nelson JC et coll. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006;35:337-44.

48. Jackson LA, Nelson JC, Berson P et coll. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol. 2006;35:345-52.

49. Simonsen L, Taylor RJ, Viboud C et coll. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007;7:658-66.

50. Simonsen L, Viboud C, Taylor RJ. Effectiveness of influenza vaccination [letter]. N Engl J Med. 2007;357:2729-30.

51. Thomas PG, Keating R, Hulse-Post DJ, et coll. Cell-mediated protection in influenza infection. Emerg Infect Dis. 2006;12:48-54.

52. Anema A, Mills E, Montaner J et coll. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med. 2008;19:419-23.

53. Cooper C, Hutton B, Fergusson D et coll. A review of influenza vaccine immunogenicity and efficacy in HIV-infected adults. Can J Infect Dis Med Microbiol. 2008;19:419-23.

54. Scharpe J, Evenepoel P, Maes B et coll. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant. 2008;8(2):332-7.

55. Manuel O, Humar A, Chen MH et coll. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant. 2007;7(11):2567-72.
56. Englehard D, Nagler A, Hardan I et coll. Antibody response to a two-dose regimen of influenza vaccine in allogenic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 1993;11:1–5.

57. Buxton JA, Skowronski DM, Ng H et coll. Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks. J Infect Dis. 2001;184:188–91.

58. Ljungman P, Nahi H, Linde A et coll. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised case study. Br J Haematol. 2005;130:96–8.

59. McElhaney JE, Hooton JW, Hooton N et coll. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine. 2005;23:3294–300.

60. Gross PA, Weksler ME, Quinnan GV et coll. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol. 1987;25:1763–5.

61. Van Damme P, Arnou R, Fiquet A, et coll. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomized comparative study. BMC Infect Dis. 2010;10:134

62. Ritzwoller DP, Bridges CB, Shetterley S et coll. Effectiveness of the 2003–2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics. 2005;116(1):153–9.

63. Neuzil KM, Jackson LA, Nelson J et coll. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006;194:1032–9.

64. Shuler CM, Iwamoto M, Bridges CB. Vaccine effectiveness against medically-attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003–2004. Pediatrics. 2007;119:587–95.

65. Allison MA, Daley MF, Crane LA et coll. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003–2004 season. J Pediatr. 2006;149(6):755–62.

66. Englund JA, Walter EB, Fairchok MP et coll. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics. 2005;115(4):1039–47.

67. Skowronski dM, Hottes TS, De Serres et al. Influenza B/ Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of B/Yamagata. Ped Inf Dis J. 2011;30: 833–39.

68. Skowronski DM, Hottes TS, Chong M, et coll. Randomized controlled trial of dose-response to influenza vaccine in children 6-23 months of age. Pediatrics. Epub 2011 July 18

69. Comité consultatif national de l'immunisation (CCNI) Guide canadien d'immunisation Septième édition – 2006 Ottawa: Travaux publics et services gouvernementaux du Canada. Disponible au : http://www.phac-aspc.gc.ca/publicat/cig-gci/index-fra.php

70. Comité consultatif national de l'immunisation (CCNI) Déclaration sur le thimérosal. RMTC 2003;29(DCC-1):1–12.

71. Comité consultatif national de l'immunisation (CCNI) Mise à jour de la déclaration sur le thimérosal. RMTC 2007;33(DCC-6):1–13.

72. Gerber JS, Offit PA. Vaccines and autism: a tale of shifting hypotheses. Clin Infect Dis. 2009;48:456–61.

73. Comité consultatif national de l'immunisation (CCNI) Déclaration additionnelle pour la saison grippale 2002-2003 : mise à jour sur le syndrome oculo-respiratoire associé à la vaccination antigrippale. RMTC. 2002;28(DCC-6):1–8.

74. Skowronski DM, Strauss B, Kendall P et coll. Low risk of recurrence of oculorespiratory syndrome following influenza revaccination. CMAJ. 2002;167(8):853–8.

75. De Serres G, Skowronski DM, Guay M et coll. Recurrence risk of oculorespiratory syndrome after influenza vaccination: randomized controlled trial of previously affected persons. Arch Intern Med. 2004;164(20):2266–72.

76. Langmuir AD, Bregman DJ, Kurland LT et coll. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol. 1984;119(6):841–79.
77. Institute of Medicine. Immunization Safety Review: Influenza Vaccines and Neurological Complications. Washington, D.C.: Institute of Medicine of the National Academies; 2008.

78. Lasky T, Terracciano GJ, Magder L et coll. The Guillain-Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med. 1998;339(25):1797–802.

79. Juurlink DN, Stukel TA, Kwong J et coll. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med. 2006;166(20):2217–21.

80. Prothro C, Kudish K, Fielin M et coll. Preliminary results: surveillance for Guillain-Barre syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine – United States, 2009–2010. MMWR. 2010;59:657–61.

81. McLean M, Duclos P, Jacob P et coll. Incidence of Guillain-Barré syndrome in Ontario and Quebec, 1983–1989, using hospital service databases. Epidemiology. 1994;5(4):443–8.

82. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366(9497):1653–66.

83. Sivadon-Tardy V, Orlikowski D, Porcher R et coll. Guillain-Barré syndrome and influenza virus infection. Clin Infect Dis. 2009;48(1):48–56.

84. Lehmann HC, Hartung HP, Kieseier BC, et coll. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010;10:643-51.

85. Tam CC, O'Brien SJ, Petersen I, et coll. Guillain-Barré syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS One. 2007 Apr 4;2(4):e344.

86. Stowe J, Andrew N, Wise L, et coll. Investigation of temporal association of Guillain-Barré Syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research database. Am J Epidemiol. 2009;169:382–8.

87. James JM, Zeiger RS, Lester MR, et coll. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr. 1998;133:624-8.

88. Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics. 2010;125:e1024–30.

89. Gagnon R, Primeau M, Des Roches A, et coll, on behalf of the PHAC-CIHR Influenza Research Network (PCIRN). Safe vaccination of egg-allergic patients with an adjuvanted pandemic H1N1 vaccine. J Allergy Clin Immunol. 2010;126(2): 317-23 E pub 2010 Jun 25.

90. Greenhawt MJ, Chernin AS, Howe L, et coll. The safety of the H1N1 influenza A vaccine in egg allergic individuals. Ann Allergy Asthma Immunol. 2010;105:387-93.

91. Schuler JE, King WJ, Dayneka NL, et coll. Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease. Can J Public Health. 2011;102:196-9.

92. Howe LE, Conlon AS, Greenhawt MJ, et coll. Safe administration of seasonal influenza vaccine to children with egg allergy of all severities. Ann Allergy Asthma Immunol. 2011;106(5):446-7. Epub 2011 Feb 24.

93. Canadian Society of Allergy and Clinical Immunology. Statement: administration of H1N1 and seasonal influenza vaccine to egg allergic individuals. 2009. Available from: http://www.csaci.ca/include/files/CSACI_H1N1_Statement.pdf.

94. Greenhawt MJ, Li JT (eds). Administering influenza vaccine to egg allergic recipients: a focused practice parameter update. Ann Allergy Asthma Immunol. 2011;106:11-6.

95. Li JT, Rank MA, Squillace DL, et coll. Ovalbumin content of influenza vaccines. J Allergy Clin Immunol. 2010;125:1412-3; author reply 1413-4. E pub 2010 May 7.

96. Waibel KH, Gomez R. Ovalbumin content in 2009 to 2010 seasonal and H1N1 monovalent influenza vaccines. J Allergy Clin Immunol. 2010 Jan;125:749-51, 751 e1. E pub 2010 Jan 8.

97. Agence de la santé publique du Canada. Rapport final sur les résultats de la Conférence nationale de concertation sur les maladies évitables par la vaccination au Canada. RMTC. 2008;34S2:28-32. Disponible au : http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/08vol34/34s2/index-fra.php
98. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis. 2008;197:490–502.

99. Intensive-care patients with severe novel influenza A (H1N1) virus infection—Michigan, June 2009. MMWR Morb Mortal Wkly Rep. 2009;58(27):749–52.

100. Jain S, Kamimoto L, Bramley AM, et coll. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med. 2009;361(20):1935–44.

101. Kumar A, Zarychanski R, Pinto R, et coll. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302(17):1872–9.

102. The ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009;361(20):1925–34.

103. Morgan OW, Bramley A, Fowlkes A, et coll. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS One. 2010;5(3):e9694.

104. Fezeu L, Julia C, Bitu, et coll. Obesity is associated with higher risk of intensive care admission and detah in influenza A(H1N1) patients: a systematic review and meta-analysis. Obes Rev. 2011 E pub 2011 Apr 4.

105. Falagas ME, Koletsi PK, Baskouta E. Pandemic A9H1N10 2009 influenza: review of the Southern Hemisphere experience. Epidemiol Infect. 2011;139:27–40.

106. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis. 2011;53(5):413-21.

107. Simonsen L, Fukuda K, Schonberger LB, et coll. The impact of influenza epidemics on hospitalizations. J Infect Dis. 2000;181:831–7.

108. Schanzer DL, Tam TW, Langley JM, et coll. Influenza-attributable deaths, Canada, 1990–1999. Epidemiol Infect. 2007;1–8.

109. Schanzer DL, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J. 2006;25(9):795–800.

110. Izurieta HS, Thompson WW, Kramarz P, et coll. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342(4):232–9.

111. Skowronski DM, Woolcott JC, Tweed SA, et coll. Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada. Vaccine. 2006;24(19):4222–32.

112. Black SB, Shinefield HR, France EK, et coll. Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. Am J Perinatol. 2004;6:333–9.

113. Schanzer DL, Langley JM, Tam TW. Influenza-attributed hospitalization rates among pregnant women in Canada 1994–2000. J Obstet Gynaecol Can. 2007;29:622–9.

114. Tuyishime JD, De Wals P, Moutquin JM, et coll. Influenza-like illness during pregnancy: results from a study in the eastern townships, province of Quebec. J Obstet Gynaecol Can. 2003;25:1020–5.

115. MacDonald NE, Riley LE, Steinhoff MC. Influenza immunization in pregnancy. Obstet Gynecol. 2009; 114:206–8.

116. Skowronski DM, De Serres G. Is routine influenza immunization warranted in early pregnancy? Vaccine. 2009; 27:4754–70.

117. McNeil SA, Halperin B, MacDonald NE. Influenza in pregnancy: the case for prevention. Adv Exp Med Biol. 2009; 634:161–83.

118. Mak TK, Mangtani P, Leese J, et coll. Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis. 2008;8:44–52.

119. Neuzil KM, Reed GW, Mitchel EF, et coll. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1997;148:1094–8.

120. Dodds L, McNeil SA, Fell SB, et coll. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. CMAJ. 2007;176:463–8.
121. Hartert TV, Neuzil KM, Shintani AK, et coll. Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season. Am J Obstet Gynecol. 2003;189:1705–12.

122. Rasmussen SA, Jamieson DJ, Breese JS. Pandemic influenza and pregnant women. Emerg Infect Dis. 2008;14:95–100.

123. Siston AM, Rasmussen SA, Honein MA, et coll. Pandemic 2009 influenza A (H1N1) virus illness among pregnant women in the United States. JAMA. 2010;303:1517–25.

124. Louie JK, Acosta M, Jamieson DJ, et al, for the California Pandemic (H1N1) Working Group. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2010;362:27–35.

125. Helferty M, Vachon J, Tarasuk J, et coll. Incidence of hospital admissions and severe outcomes during the first and second waves of pandemic (H1N1) 2009. CMAJ. 2010;182:1981-7. E pub 2010 Nov 8.

126. Ashley J, Smith T, Dunell K. Deaths in Great Britain associated with the influenza epidemic of 1989/90. Pop Trends. 1991;65:16–20.

127. Mulloolly JP, Barker WH, Nolan TF. Risk of acute respiratory disease among pregnant women during influenza A epidemics. Public Health Rep. 1986;101:205–10.

128. Schoenbaum SC, Weinstein L. Respiratory infection in pregnancy. Clin Obstet Gynecol. 1979;22:293–300.

129. Widelock D, Csizmas L, Klein S. Influenza, pregnancy and fetal outcome. Public Health Rep. 1963;78:1–11.

130. Houseworth J, Langmuir AD. Excess mortality from epidemic influenza, 1957-1966. Am J Epidemiol. 1974;100:40–8.

131. Callaghan WM, Chu SY, Jamieson DJ. Deaths from seasonal influenza among pregnant women in the United States, 1998–2005. Obstet Gynecol. 2010;115:919–23.

132. Hulka JF. Effectiveness of polyvalent influenza vaccine in pregnancy: report of a controlled study during an outbreak of Asian influenza. Obstet Gynecol. 1964;23:830–7.

133. Munoz FM, Greisinger AJ, Wehmanen OA, et coll. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol. 2005;192:1098–106.

134. France EK, Smith-Ray R, McClure D, et coll. Impact of maternal influenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants. Arch Pediatr Adolesc Med. 2006;160:1277–83.

135. Zaman K, Roy E, Arifeen SE, et coll. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med. 2008;359:1–10.

136. Steinhoff MC, Omer SB, Roy E, et coll. Influenza immunization in pregnancy—antibody responses in mothers and infants. N Engl J Med. 2010;362:1644–5.

137. Eick AA, Uyeki TM, Klimov A, et coll. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med. 2011;165:104-11. Epub 2010 Oct 4.

138. Tamma PD, Ault KA, del Rio C, et coll. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol. 2009;201:547–52.

139. Moro PL, Broder K, Zheteyeva Y, et coll. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol. 2011;204:146.e1-7. E pub 2010 Oct 20.

140. Agence de la santé publique du Canada. Rapport de surveillance du vaccin - Les effets secondaires suivant l'immunisation Mise à jour : 27 avril 2010. Disponible au : http://www.phac-aspc.gc.ca/alert-alerte/h1n1/vacc/addeve-fra.php

141. European Medicines Agency. Fifteenth Pandemic Pharmacovigilance update. 8 April 2010. Disponible au : http://www.ema.europa.eu/pdfs/influenza/21323810en.pdf

142. Heinonen OP, Shapiro S, Monson RR, et coll. Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy. Int J Epidemiol. 1973;2:229–35.

143. Heinonen OP, Slone D, Shapiro S. Immunizing agents. In: Kaufman DW, editor. Birth defects and drugs in pregnancy. Boston (MA): Littleton Publishing Sciences Group; 1977. p. 314–21.
144. Sumaya CV, Gibbs RS. Immunization of pregnant women with influenza A/New Jersey/76 virus vaccine:reactogenicity and immunogenicity in mother and infant. J Infect Dis. 1979;140:141–6.

145. Englund JA, Mbawuike IN, Hammill H, et coll. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis. 1993;68:647–56.

146. Deinard AS, Ogburn Jr P. A/NJ/8/76 influenza vaccination program: effects on maternal health and pregnancy outcome. Am J Obstet Gynecol. 1981;140:240–5.

147. Groom AV, Jim C, Laroque M, et coll. Pandemic influenza preparedness and vulnerable populations in tribal communities. Am J Public Health. 2009;99 Suppl 2: S271–8.

148. Samet JM, Key CR, Kutvirt DM, et coll. Respiratory disease mortality in New Mexico's American Indians and Hispanics. Am J Public Health. 1980;70(5): 492–7.

149. La Ruche G, Tarantola A, Barboza P, et coll. for the Epidemic Intelligence Team at InVS. The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific. Euro Surveill. 2009;14(42):1–6.

150. Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives – 12 states, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(48):1341–4.

151. Zarychanski R, Stuart TL, Kumar A, et coll. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ. 2010;182:257–64.

152. Jouvet P, Hutchison J, Pinto R, et coll. Critical illness in children with influenza A/pH1N1 2009 infection in Canada. Paediatr Crit Care Med. 2010;11:603-9.

153. Campbell A, Rodin R, Kropp R, et coll. Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza. CMAJ. 2010;182:349-55. E pub 2010 Feb 16.

154. International Center for Education Statistics. Individuals, families and children in poverty. In: Status and trends in the education of American Indians and Alaska Natives. 2008. Disponible au : http://nces.ed.gov/pubs2008/nativetrends/ind_1_6.asp.

155. Canada. Points saillants du rapport de la Commission royale sur les peuples autochtones - À l'aube d'un rapprochement. 1996. Disponible au : http://www.ainc-inac.gc.ca/ap/pubs/rpt/rpt-fra.asp

156. Clark M, Riben P, Nowgesic E. The association of housing density, isolation and tuberculosis in Canadian First Nations communities. Int J Epidemiol. 2002;31:940-3.

157. Larcombe L, Rempel JD, Dembinski I, et coll. Differential cytokine genotype frequencies among Canadian Aboriginal and Caucasian populations. Genes Immun. 2005;6:140-4.

158. Hayward AC, Harling R, Wetten S, et coll. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ. 2006;333(7581):1241.

159. Potter J, Stott DJ, Roberts MA, et coll. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis. 1997;175(1):1–6.

160. Pearson ML, Bridges CB, Harper SA. Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-2):1–16.

161. Carman WF, Elder AG, Wallace LA, et coll. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet. 2000;355(9198):93–7.

162. Lemaitre M, Meret T, Rothan-Tondeur M, et coll. Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial. J Am Geriatr Soc. 2009;57:1580–6.
163. Wilde JA, McMillan JA, Serwint J, et coll. Effectiveness of influenza vaccine in health care professionals:a randomized trial. JAMA. 1999;281(10):908–13.

164. Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J. 1999;18(9):779–83.

165. Shugarman LR, Hales C, Setodji CM, et coll. The influence of staff and resident immunization rates on influenza-like illness outbreaks in nursing homes. J Am Med Dir Assoc 2006;7(9):562–7.

166. Bridges CB, Lim W, Hu-Primmer J, et coll. Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997–1998. J Infect Dis. 2002;185(8):1005–10.

167. Puzelli S, Di Trani L, Fabiani C, et coll. Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003. J Infect Dis. 2005;192(8):1318–22.

168. Tweed SA, Skowronski DM, David ST, et coll. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis. 2004;10(12):2196–9.

169. Skowronski DM, Li Y, Tweed SA, et coll. Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada. CMAJ. 2006;176(1):47–53.

170. Department of Health UK. Flu vaccination for poultry workers. Department of Health UK; 2007. Disponible au : http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAnd-Guidance/DH_063041.

171. Gray GC, Trampel DW, Roth JA. Pandemic influenza planning: Shouldn't swine and poultry workers be included? Vaccine. 2007 25(22):4376–81.

172. Turner DA, Wailoo AJ, Cooper NJ, et coll. The cost-effectiveness of influenza vaccination of healthy adults 50–64 years of age. Vaccine. 2006;24(7):1035–43.

173. CATMAT. Statement on travel, influenza and prevention. Can Commun Dis Rep. 2005;31(ACS-2):1–8.

174. Beyer WEP, Nauta JJP, Palache AM, et coll. Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis. Vaccine. 2011, doi:10.1016/j.vaccine.2011.05.040.

175. Loeb M, Russell ML, Moss L, et coll. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010;303:943–50.

176. Monto AS, Davenport FM, Napier JA, et coll. Modification of an outbreak of influenza in Tecumseh Michigan, by vaccination of schoolchildren. J Infect Dis. 1970;122(1):16–25.

177. Esposito S, Marchisio P, Cavagna R, et coll. Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine. 2003;21(23):3162–8.

178. Piedra PA, Gaglani MJ, Kozinetz CA, et coll. Herd immunity in adults against influenza-like illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005;23(13):1540–8.

179. Reichert TA, Sugaya N, Fedson DS, et coll. The Japanese experience with vaccinating school children against influenza. N Engl J Med. 2001;344(12):889–96.

180. Hurwitz ES, Haber M, Chang A, et coll. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA. 2000;284(13):1677–82.

181. Rudenko LG, Slepushkin AN, Monto AS, et coll. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis. 1993;168(4):881–7.

182. King JC Jr, Stoddard JJ, Gaglani MJ, et coll. Effectiveness of school-based influenza vaccination. N Engl J Med. 2006;355(24):2523–32.

183. Jordan R, Connock M, Albon E, et coll. Universal vaccination of children against influenza : are there indirect benefits to the community? A systematic review of the evidence. Vaccine. 2006;24:1047–62.
184. Kwong JC, Stukel TA, Lim W, et coll. The effect of universal influenza immunization on mortality and health care use. PLoS Med. 2008;5(10):1440–52.

185. Kwong JC, Maaten S, Upshur REG, et coll. The effect of universal influenza immunization on antibiotic prescriptions: an ecological study. Clin Infect Dis. 2009;49:750–6.

186. Sander B, Kwong JC, Bauch CT, et coll. Economic appraisal of Ontario's universal influenza immunization program: a cost-utility analysis. PLoS Med. 2010;7:e10000256.

187. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. 2010;59(No. RR-8):1-62.

188. Poland GA, Morse D. Improving the public health: the U.S. recommendation for universal influenza immunization. Vaccine. 2010;28:2799–800.

189. Kwong JC, Ge H, Rosella LC, et coll. School-based influenza vaccine delivery, vaccination rates, and healthcare use in the context of a universal influenza immunization program: An ecological study. Vaccine 2010;28:2722-2729.

190. Cawley J, Hull HF, Rousculp MD. Strategies for implementing school-located influenza vaccination of children: a systematic literature review. J Sch Health 2010;80:167-75.

191. Hull HF, Ambrose CS. Current experience with school-located influenza programs in the United States. A review of the medical literature. Human Vaccines 2011;7:153-60.

192. Elder A, O'Donnell B, McCruden E, et coll. Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993-4 epidemic: results of serum testing and questionnaire. BMJ. 1996;313:1241-2.

193. Lester RT, McGeer A, Tomlinson G, et coll. Use of, effectiveness of and attitudes regarding influenza vaccine among housestaff. Infect Control Hosp Epidemiol. 2003;24:839-44.

194. Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database of Systematic Reviews 2010, Issue 2. Art. No.: CD005187. DOI: 10.1002/14651858. CD005187.pub3.

195. Skowronski DM, De Serres G, Dickinson J, et coll. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis. 2009;199:168-79.

196. Skowronski DM, Janjua NZ, De Serres G, et coll. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ. 2011;342:c7297. Epub 2011 Feb 3.

197. PCIRN/CIHR Influenza Research Network (PCIRN). Vaccine Effectiveness: SOS network. Disponible au : http://www.pcirn.ca/research-themes/vaccine-effectiveness.html

198. Squarcione S, Sgricia S, Biasio LR, et coll. Comparison of the reactogenicity and immunogenicity of a split and subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine. 2003;21:1268-1274.